These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). Horn L; Spigel DR; Vokes EE; Holgado E; Ready N; Steins M; Poddubskaya E; Borghaei H; Felip E; Paz-Ares L; Pluzanski A; Reckamp KL; Burgio MA; Kohlhäeufl M; Waterhouse D; Barlesi F; Antonia S; Arrieta O; Fayette J; Crinò L; Rizvi N; Reck M; Hellmann MD; Geese WJ; Li A; Blackwood-Chirchir A; Healey D; Brahmer J; Eberhardt WEE J Clin Oncol; 2017 Dec; 35(35):3924-3933. PubMed ID: 29023213 [TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449 [TBL] [Abstract][Full Text] [Related]
5. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784 [TBL] [Abstract][Full Text] [Related]
6. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986 [TBL] [Abstract][Full Text] [Related]
8. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. Hellmann MD; Paz-Ares L; Bernabe Caro R; Zurawski B; Kim SW; Carcereny Costa E; Park K; Alexandru A; Lupinacci L; de la Mora Jimenez E; Sakai H; Albert I; Vergnenegre A; Peters S; Syrigos K; Barlesi F; Reck M; Borghaei H; Brahmer JR; O'Byrne KJ; Geese WJ; Bhagavatheeswaran P; Rabindran SK; Kasinathan RS; Nathan FE; Ramalingam SS N Engl J Med; 2019 Nov; 381(21):2020-2031. PubMed ID: 31562796 [TBL] [Abstract][Full Text] [Related]
9. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. Hellmann MD; Ciuleanu TE; Pluzanski A; Lee JS; Otterson GA; Audigier-Valette C; Minenza E; Linardou H; Burgers S; Salman P; Borghaei H; Ramalingam SS; Brahmer J; Reck M; O'Byrne KJ; Geese WJ; Green G; Chang H; Szustakowski J; Bhagavatheeswaran P; Healey D; Fu Y; Nathan F; Paz-Ares L N Engl J Med; 2018 May; 378(22):2093-2104. PubMed ID: 29658845 [TBL] [Abstract][Full Text] [Related]
10. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A; Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723 [TBL] [Abstract][Full Text] [Related]
11. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. Borghaei H; Gettinger S; Vokes EE; Chow LQM; Burgio MA; de Castro Carpeno J; Pluzanski A; Arrieta O; Frontera OA; Chiari R; Butts C; Wójcik-Tomaszewska J; Coudert B; Garassino MC; Ready N; Felip E; García MA; Waterhouse D; Domine M; Barlesi F; Antonia S; Wohlleber M; Gerber DE; Czyzewicz G; Spigel DR; Crino L; Eberhardt WEE; Li A; Marimuthu S; Brahmer J J Clin Oncol; 2021 Mar; 39(7):723-733. PubMed ID: 33449799 [TBL] [Abstract][Full Text] [Related]
12. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial. Wu YL; Lu S; Cheng Y; Zhou C; Wang J; Mok T; Zhang L; Tu HY; Wu L; Feng J; Zhang Y; Luft AV; Zhou J; Ma Z; Lu Y; Hu C; Shi Y; Baudelet C; Cai J; Chang J J Thorac Oncol; 2019 May; 14(5):867-875. PubMed ID: 30659987 [TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB Lancet; 2016 Apr; 387(10027):1540-1550. PubMed ID: 26712084 [TBL] [Abstract][Full Text] [Related]
14. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Rittmeyer A; Barlesi F; Waterkamp D; Park K; Ciardiello F; von Pawel J; Gadgeel SM; Hida T; Kowalski DM; Dols MC; Cortinovis DL; Leach J; Polikoff J; Barrios C; Kabbinavar F; Frontera OA; De Marinis F; Turna H; Lee JS; Ballinger M; Kowanetz M; He P; Chen DS; Sandler A; Gandara DR; Lancet; 2017 Jan; 389(10066):255-265. PubMed ID: 27979383 [TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer. Wang C; Yu X; Wang W Medicine (Baltimore); 2016 Dec; 95(52):e5539. PubMed ID: 28033249 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice. Calpe-Armero P; Ferriols-Lisart R; Ferriols-Lisart F; Pérez-Pitarch A Chemotherapy; 2017; 62(6):374-380. PubMed ID: 29045938 [TBL] [Abstract][Full Text] [Related]
17. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Antonia SJ; Borghaei H; Ramalingam SS; Horn L; De Castro Carpeño J; Pluzanski A; Burgio MA; Garassino M; Chow LQM; Gettinger S; Crinò L; Planchard D; Butts C; Drilon A; Wojcik-Tomaszewska J; Otterson GA; Agrawal S; Li A; Penrod JR; Brahmer J Lancet Oncol; 2019 Oct; 20(10):1395-1408. PubMed ID: 31422028 [TBL] [Abstract][Full Text] [Related]
18. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Barlesi F; Vansteenkiste J; Spigel D; Ishii H; Garassino M; de Marinis F; Özgüroğlu M; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Ellers-Lenz B; Bajars M; Ruisi M; Park K Lancet Oncol; 2018 Nov; 19(11):1468-1479. PubMed ID: 30262187 [TBL] [Abstract][Full Text] [Related]